Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-5T4/exatecan antibody-drug conjugate TUB-030

An antibody-drug conjugate (ADC) composed of a Fc-silenced, humanized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the oncofetal antigen 5T4 and site-specifically conjugated, via a cleavable linker, to the cytotoxic agent and DNA topoisomerase I inhibitor exatecan, with potential antineoplastic activity. Upon administration of anti-5T4/exatecan ADC TUB-030, the anti-5T4 antibody moiety selectively targets and binds to cells expressing 5T4. After internalization and cleavage within the tumor cell, exatecan is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in DNA damage, cell cycle arrest and apoptosis in tumor cells overexpressing 5T4. In addition, TUB-030 induces a bystander effect, thereby killing neighboring tumor cells that don't necessarily express 5T4 in the tumor environment (TME). 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types while its expression is limited in normal adult tissues; its expression is correlated with increased invasiveness.
Synonym:anti-5T4 ADC TUB-030
anti-5T4 antibody-drug conjugate TUB-030
anti-5T4/exatecan ADC TUB-030
Code name:TUB 030
TUB-030
TUB030
Search NCI's Drug Dictionary